CompletedNCT06382571Updated Apr 24, 2024

Factors Associated With Sub - Targeted Therapeutic Dose Of Renin - Angiotensin Blockage Among Chronic Heart Failure With Reduced Ejection Fraction Patients

An observational study in Heart Failure With Reduced Ejection Fraction, sponsored by Chulalongkorn University. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-24.

Sponsored by Chulalongkorn University · Observational

Study type: Observational
Model: Cohort
Time perspective: Retrospective
Enrollment: 396
Ages: 18 Years and older
Sex: All

Study summary

Objective: To analyze factors associated with Thai heart failure with reduced ejection fraction patients who received sub-target doses of Angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor-neprilysin inhibitors (ARNIs), and angiotensin receptor blockers (ARBs).

Methods: The retrospective cohort study was designed to collect data on Thai heart failure with reduced ejection fraction patients at Out-patient Clinic, Trat Hospital and Phrapokklao Hospital from January 2016 to December 2020. Thirteen factors were analyzed to determine their association with the sub-target group.

Conditions studied

Heart Failure With Reduced Ejection Fraction

In context

Lead sponsor

Chulalongkorn University is the lead sponsor of 321 studies on the registry; 64 are open to participants now.

Browse Chulalongkorn University studies →

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Sampling method: Non-probability sample

Study population

Adult out - patients who were first diagnosed be heart failure with left vetricular ejection fraction less than 40% and recieved one of ACEIs,ARBs,ARNI drugs.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients who were first diagnosed be heart failure with left ventricular ejection fraction less than 40%.
Received one of ACEIs,ARBs,ARNI drugs.

Exclusion criteria

Exclusion Criteria:

Electronic medical records was not complete enough to analyse.
Patients who had history of heart transplantation or had heart transplantation plan in last 12 months.

Study design

Observational model: Cohort
Time perspective: Retrospective
Enrollment: 396 participants (actual)
Patient registry: No

Groups and cohorts

Sub - target dose group
Patients who received sub - target dose of Angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor-neprilysin inhibitors (ARNIs), and angiotensin receptor blockers (ARBs).
Drug: Renin-Angiotensin System Inhibitor
Target dose group
Patients who received target dose or maximal tolerated dose of Angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor-neprilysin inhibitors (ARNIs), and angiotensin receptor blockers (ARBs)
Drug: Renin-Angiotensin System Inhibitor

Interventions

DrugRenin-Angiotensin System Inhibitor

What researchers measure

Primary outcomes

factors associated with sub - target dose of ACEIs,ARBs,ARNI
factors associated with Thai heart failure with reduced ejection fraction patients who received sub-target doses of Angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor-neprilysin inhibitors (ARNIs), and angiotensin receptor blockers (ARBs).
Time frame: 12 months

Study locations

No study locations are listed for this record.

Timeline

Tracking since Sep 25, 2026

ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2016 to primary completion in Dec 2020, 59 months.

How these figures are worked out, and which studies are left out of them.

Registered: Feb 20, 2024
First posted: Apr 24, 2024
StartActual: Jan 1, 2016
Primary completionActual: Dec 31, 2020
CompletionActual: Dec 31, 2021
Last update: Apr 24, 2024

What these dates mean

Start.: When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.: When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.: When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.: Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.

No changes since tracking began. The registry record was last updated on Apr 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT06382571
Lead sponsor: Chulalongkorn University
Responsible party: Sponsor
First posted: Apr 24, 2024
Start date: Jan 1, 2016
Primary completion: Dec 31, 2020
Completion: Dec 31, 2021
Last update: Apr 24, 2024

Oversight

FDA-regulated drug: Yes
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Chulalongkorn University →

Start the discussion